Tian X et al. (2022), Strongylocentrotus nudus Eggs Polysaccharide En...

ECB-ART-50401

Front Pharmacol 2022 Jan 01;13:807440. doi: 10.3389/fphar.2022.807440.

Show Gene links Show Anatomy links

Strongylocentrotus nudus Eggs Polysaccharide Enhances Macrophage Phagocytosis Against E.coli Infection by TLR4/STAT3 Axis.

Tian X , Guo M , Zhang X , Guo L , Lan N , Cheng Y , Han Y , Wang M , Peng Z , Zhou C , Fan H .

???displayArticle.abstract???
Antibiotics resistance is one of the most significant public health threats globally. Strategies that strengthen host defenses to control pathogen infection has become a hot research field. Macrophages are part of early host defense mechanisms, and are activated via host pattern recognition receptors (PRRs), such as Toll-like receptor 4 (TLR4), which then facilitates phagocytosis and elimination of invading pathogens. However, few activators of PRRs have been approved for clinical use because of their toxic effects. This study aimed to investigate whether Strongylocentrotus nudus eggs polysaccharide (SEP), a non-toxic extract from seafood, contributes to host defense against bacterial infection. Results showed that SEP promoted bacterial clearance by enhancing phagocytosis by macrophages during E. coli infection in vitro, but was inhibited by TLR4 specific inhibitor TAK-242, STAT3 inhibitor Stattic or blockade of CD64. In addition, SEP protected mice from E. coli induced mortality, reduced pulmonary inflammation and inhibited dissemination of bacteria to organs, while TAK-242 retarded the protection of SEP. Overall, SEP strengthened innate host defense and improved the outcome in bacterial infection, suggesting that SEP could be used as a potential immunomodulator in host-directed therapies.

???displayArticle.pubmedLink??? 35370674
???displayArticle.pmcLink??? PMC8968116
???displayArticle.link??? Front Pharmacol

???attribute.lit??? ???displayArticles.show???

	FIGURE 1. SEP protects against E. coli infection by enhancing host defense. (A) Molecular structure of SEP. (B) The effect of SEP on macrophages phagocytosis of live E. coli by gentamicin protection assay. RAW264.7 cells were administrated with Cyt D (10 μM) for 2 h prior to E. coli infection. (C) The effect of SEP on macrophages phagocytosis by fluorescence intensity. RAW264.7 cells were fed with pHrodo-conjugated inactivated E. coli bioparticles for 1 h and phagocytosis was quantified by the fluorescence. (D) The experimental design of E. coli infection and SEP treatment in mice. Mice were pre-treated with SEP (25 mg/kg) or vehicle (saline) by i. v. every 3 days for three times, and infected with E. coli (9 × 108 CFU per mouse, i. p.) on the eighth day. Then the survival of mice (E) were evaluated. (n = 10). (F) Mice were pre-treated with SEP (25 mg/kg, i. v.) and infected with E. coli (3 × 108 CFU per mouse, i. p.) on day eight, then sacrificed at 18 h post-infection. (n = 8). CFU of E. coli in tissue homogenates of lung, spleen, liver, and peritoneal lavage fluid were detected. (G) Lung sections were stained with H&E. (H) Myeloperoxidase (MPO) value were detected in the lung tissue. (I) The expression of IL-1β, TNF-α and IL-6 in the lungs were measured by ELISA. All data are represented as mean ± SEM acquired in triplicate determinations. p < 0.05, p < 0.01, **p < 0.001.
	FIGURE 2. SEP promotes macrophages phagocytosis via TLR4. RAW264.7 cells were pre-treated with TLR2 inhibitor C29 (50 μM) or TLR4 inhibitor TAK-242 (20 μM) for 2 h, then stimulated with SEP (100 μg/ml) for another 24 h. (A) Phagocytosis of live E. coli by macrophages were measured by gentamicin protection assay. (B) Phagocytosis of pHrodo-E. coli by macrophages were quantified by fluorescence intensity. (C) The positive cell rates for phagocytosis of pHrodo-E. coli by macrophage were detected by flow cytometry. All data are represented as mean ± SEM acquired in triplicate determinations. ****p < 0.0001. ns, not significant.
	FIGURE 3. TLR4/STAT3 signaling is involved in SEP induced phagocytosis. (A) The effects of SEP on protein levels of p-p65, p-ERK, p-JNK and p-mTOR were determined by western blot. (B) The effects of TLR4 signaling pathway inhibitors on phagocytosis of live E. coli were measured by gentamicin protection assay. RAW264.7 cells were pre-treated with NF-κB inhibitor BAY 11-7085 (2 μM), or JNK inhibitor SP610025 (5 μM), or MEK1/2 inhibitor PD184352 (5 μM), or PI3K inhibitor LY294002 (5 μM) for 2 h prior to SEP treatment. (C) Phagocytosis of pHrodo-E. coli by macrophages were quantified by fluorescence intensity. (D, E) The effects of SEP on protein levels of p-STAT1, p-STAT3 were determined by western blot. The effects of Stattic (5 μM) or Fludarabine (20 μM) on phagocytosis of pHrodo-E. coli were measured by flow cytometry (F), or phagocytosis of live E. coli by gentamicin protection assay (G), or phagocytosis of pHrodo-E. coli by fluorescence intensity (H). All data are represented as mean ± SEM acquired in triplicate determinations. p < 0.05, p < 0.01, ***p < 0.0001.
	FIGURE 4. CD64 is responsible for SEP induced phagocytosis via TLR4/STAT3 signals. (A,B) The effects of SEP on the relative mRNA expression of CD64, CD32 and CD16 were determined by q-PCR. (C,D) The effects of SEP on the protein levels of CD64 and CD16/32 were determined by flow cytometry. (E) RAW264.7 cells were pre-treated with SEP (100 μg/ml) for 24 h, and followed by incubation with 2 μg/ml anti-CD64 or anti-CD16/32 blocking antibodies for 1 h prior to pHrodo-E. coli infection. Then macrophage phagocytosis was quantified by the fluorescence. (F) The effects of blocking CD64 or anti-CD16/32 on phagocytosis of live E. coli by macrophages were measured by gentamicin protection assay. All data are represented as mean ± SEM acquired in triplicate determinations. p < 0.05, p < 0.001,**p < 0.0001. ns, not significant.
	FIGURE 5. SEP promotes filopodia formation via TLR4/STAT3 axis. (A) The effects of SEP on the filopodia formation of macrophages. RAW264.7 cells were administrated with Src family inhibitor AZD0530 (10 μM) or ROCK1 inhibitor Y-27632 (20 μM) for 2 h prior to E. coli infection. The cellular filamentous actin were stained with rhodamine phalloidin and the cellular DNA with DAPI. (B) The effects of SEP on protein levels of p-Src and p-Lyn were determined by western blot. (C) The effects of AZD0530 or Y-27632 on SEP induced phagocytosis of pHrodo-E. coli were measured by fluorescence intensity, (D) or phagocytosis of live E. coli by gentamicin protection assay, or (E) phagocytosis of pHrodo-E. coli by flow cytometry. (F) The effects of TAK-242 or Stattic on SEP induced filopodia formation. (G,H) The effects of TAK-242, or C29, or Stattic, or Fludarabine on SEP induced protein levels of p-Src and p-Lyn were determined by western blot. *p < 0.001, **p < 0.0001.
	FIGURE 6. Inhibition of TLR4 abolishes the protection of SEP against E. coli infection. (A) The experimental design of SEP administration in mice. Mice were treated with SEP (25 mg/kg) or vehicle (saline) by i. v. every 3 days for three times, and sacrificed on the eighth day. The total protein and mRNA were extracted from mice peritoneal macrophages. (B) The protein levels of p-STAT3, p-Src and p-Lyn in the peritoneal macrophages were determined by western blot. (C) The relative mRNA levels of CD64, CD32 and CD16 in the peritoneal macrophages were determined by q-PCR. (D) The experimental design of TAK-242 combined with SEP administration in mice infection model. The TAK-242 group mice were pre-treated with TAK-242 (10 mg/kg, i. p.) 2 h before administration of SEP, once every 3 days for three times. Then mice were further challenged with E. coli (3 × 108 CFU, i. p) on day eight and sacrificed at 18 h post-infection. (n = 8). (E) CFU of E. coli was detected in tissue homogenates of lung, spleen, liver, and peritoneal lavage fluid. (F) MPO value in the lung tissue. (G) The protein levels of CD64 and CD16/32 in the peritoneal macrophages were determined by flow cytometry. (H) The experimental design of TAK-242 combined with SEP administration in mice. The TAK-242 group mice were pre-treated with TAK-242 (10 mg/kg, i. p.) 2 h before administration of SEP, once every 3 days for three times, and sacrificed on the eighth day. (I) The protein levels of p-STAT3, p-Src and p-Lyn in the peritoneal macrophages were determined by western blot. All data are represented as mean ± SEM acquired in triplicate determinations. p < 0.05, p < 0.01, ***p < 0.0001.

References [+] :

Aderem, Mechanisms of phagocytosis in macrophages. 1999, Pubmed

Aderem, Mechanisms of phagocytosis in macrophages. 1999, Pubmed
Akinrinmade, CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases. 2017, Pubmed
Akira, Pathogen recognition and innate immunity. 2006, Pubmed
Anwar, Recent clinical trends in Toll-like receptor targeting therapeutics. 2019, Pubmed
Bagheri, Hydrocortisone reduces Toll-like receptor 4 expression on peripheral CD14+ monocytes in patients undergoing percutaneous coronary intervention. 2014, Pubmed
Bah, Macrophage Autophagy and Bacterial Infections. 2017, Pubmed
Bihl, Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. 2003, Pubmed
Branger, Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice. 2004, Pubmed
Brubaker, Innate immune pattern recognition: a cell biological perspective. 2015, Pubmed
Danikas, Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression. 2008, Pubmed
Fang, TLR2 mediates phagocytosis and autophagy through JNK signaling pathway in Staphylococcus aureus-stimulated RAW264.7 cells. 2014, Pubmed
Fang, Identification and activation of TLR4-mediated signalling pathways by alginate-derived guluronate oligosaccharide in RAW264.7 macrophages. 2017, Pubmed
Fensterheim, The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism. 2018, Pubmed
Fujiwara, Bacterial sphingophospholipids containing non-hydroxy fatty acid activate murine macrophages via Toll-like receptor 4 and stimulate bacterial clearance. 2013, Pubmed
Fukuda, Monophosphoryl Lipid a Attenuates Multiorgan Dysfunction During Post-Burn Pseudomonas Aeruginosa Pneumonia in Sheep. 2020, Pubmed
Gugliandolo, Involvement of TLR4 and PPAR-α Receptors in Host Response and NLRP3 Inflammasome Activation, Against Pulmonary Infection With Pseudomonas Aeruginosa. 2019, Pubmed
Hamill, Novel anti-infectives: is host defence the answer? 2008, Pubmed
Hatfield, Assessing Variability in Hospital-Level Mortality Among U.S. Medicare Beneficiaries With Hospitalizations for Severe Sepsis and Septic Shock. 2018, Pubmed
Hernandez, Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection. 2019, Pubmed
Huynh, Minor Ginsenoside Rg2 and Rh1 Attenuates LPS-Induced Acute Liver and Kidney Damages via Downregulating Activation of TLR4-STAT1 and Inflammatory Cytokine Production in Macrophages. 2020, Pubmed
Kaufmann, Host-directed therapies for bacterial and viral infections. 2018, Pubmed
Kress, Filopodia act as phagocytic tentacles and pull with discrete steps and a load-dependent velocity. 2007, Pubmed
Kuuliala, Signalling Profiles of Blood Leucocytes in Sepsis and in Acute Pancreatitis in Relation to Disease Severity. 2018, Pubmed
Laxminarayan, Access to effective antimicrobials: a worldwide challenge. 2016, Pubmed
Lei, Targeting STAT3: A crucial modulator of sepsis. 2021, Pubmed
Li, Aging-Impaired Filamentous Actin Polymerization Signaling Reduces Alveolar Macrophage Phagocytosis of Bacteria. 2017, Pubmed
Liu, Immunomodulatory activity of polysaccharides isolated from Strongylocentrotus nudus eggs. 2008, Pubmed , Echinobase
López-Collazo, Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences. 2013, Pubmed
Lv, TLR4-NOX2 axis regulates the phagocytosis and killing of Mycobacterium tuberculosis by macrophages. 2017, Pubmed
Mittal, Fcγ receptor I alpha chain (CD64) expression in macrophages is critical for the onset of meningitis by Escherichia coli K1. 2010, Pubmed
Nimmerjahn, Fcgamma receptors as regulators of immune responses. 2008, Pubmed
O'Brien, Bacterial lipoprotein induces resistance to Gram-negative sepsis in TLR4-deficient mice via enhanced bacterial clearance. 2005, Pubmed
Owen, TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection. 2020, Pubmed
Pan, GSKJ4 Protects Mice Against Early Sepsis via Reducing Proinflammatory Factors and Up-Regulating MiR-146a. 2018, Pubmed
Poltorak, Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. 1998, Pubmed
Poltorak, Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. 1998, Pubmed
Rice, A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. 2010, Pubmed
Rietschel, Bacterial endotoxin: molecular relationships of structure to activity and function. 1994, Pubmed
Romerio, Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview. 2020, Pubmed
Romero, The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. 2011, Pubmed
Rougerie, Generation of membrane structures during phagocytosis and chemotaxis of macrophages: role and regulation of the actin cytoskeleton. 2013, Pubmed
Rudd, Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. 2020, Pubmed
Shang, Traditional Chinese medicine--sea urchin. 2014, Pubmed , Echinobase
Sharma, Gentamicin Protection Assay to Determine the Number of Intracellular Bacteria during Infection of Human TC7 Intestinal Epithelial Cells by Shigella flexneri. 2019, Pubmed
Si-Tahar, Innate immunity and inflammation--two facets of the same anti-infectious reaction. 2009, Pubmed
Stark, Endothelial cell tolerance to lipopolysaccharide challenge is induced by monophosphoryl lipid A. 2016, Pubmed
Vallières, Mechanism involved in interleukin-21-induced phagocytosis in human monocytes and macrophages. 2017, Pubmed
Vergadi, Regulation of Endotoxin Tolerance and Compensatory Anti-inflammatory Response Syndrome by Non-coding RNAs. 2018, Pubmed
Wang, A polysaccharide from Strongylocentrotus nudus eggs protects against myelosuppression and immunosuppression in cyclophosphamide-treated mice. 2011, Pubmed , Echinobase
Wang, Overexpression of Toll-Like Receptor 4 Contributes to Phagocytosis of Salmonella Enterica Serovar Typhimurium via Phosphoinositide 3-Kinase Signaling in Sheep. 2018, Pubmed
Weighardt, Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. 2000, Pubmed
Xie, Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo. 2019, Pubmed , Echinobase
Yang, ADAP Y571 Phosphorylation Is Required to Prime STAT3 for Activation in TLR4-Stimulated Macrophages. 2021, Pubmed
Zhang, Toll-like receptor 4 is essential to preserving cardiac function and survival in low-grade polymicrobial sepsis. 2014, Pubmed
Zumla, Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. 2016, Pubmed

	FIGURE 1. SEP protects against E. coli infection by enhancing host defense. (A) Molecular structure of SEP. (B) The effect of SEP on macrophages phagocytosis of live E. coli by gentamicin protection assay. RAW264.7 cells were administrated with Cyt D (10 μM) for 2 h prior to E. coli infection. (C) The effect of SEP on macrophages phagocytosis by fluorescence intensity. RAW264.7 cells were fed with pHrodo-conjugated inactivated E. coli bioparticles for 1 h and phagocytosis was quantified by the fluorescence. (D) The experimental design of E. coli infection and SEP treatment in mice. Mice were pre-treated with SEP (25 mg/kg) or vehicle (saline) by i. v. every 3 days for three times, and infected with E. coli (9 × 108 CFU per mouse, i. p.) on the eighth day. Then the survival of mice (E) were evaluated. (n = 10). (F) Mice were pre-treated with SEP (25 mg/kg, i. v.) and infected with E. coli (3 × 108 CFU per mouse, i. p.) on day eight, then sacrificed at 18 h post-infection. (n = 8). CFU of E. coli in tissue homogenates of lung, spleen, liver, and peritoneal lavage fluid were detected. (G) Lung sections were stained with H&E. (H) Myeloperoxidase (MPO) value were detected in the lung tissue. (I) The expression of IL-1β, TNF-α and IL-6 in the lungs were measured by ELISA. All data are represented as mean ± SEM acquired in triplicate determinations. p < 0.05, p < 0.01, **p < 0.001.
	FIGURE 2. SEP promotes macrophages phagocytosis via TLR4. RAW264.7 cells were pre-treated with TLR2 inhibitor C29 (50 μM) or TLR4 inhibitor TAK-242 (20 μM) for 2 h, then stimulated with SEP (100 μg/ml) for another 24 h. (A) Phagocytosis of live E. coli by macrophages were measured by gentamicin protection assay. (B) Phagocytosis of pHrodo-E. coli by macrophages were quantified by fluorescence intensity. (C) The positive cell rates for phagocytosis of pHrodo-E. coli by macrophage were detected by flow cytometry. All data are represented as mean ± SEM acquired in triplicate determinations. ****p < 0.0001. ns, not significant.
	FIGURE 3. TLR4/STAT3 signaling is involved in SEP induced phagocytosis. (A) The effects of SEP on protein levels of p-p65, p-ERK, p-JNK and p-mTOR were determined by western blot. (B) The effects of TLR4 signaling pathway inhibitors on phagocytosis of live E. coli were measured by gentamicin protection assay. RAW264.7 cells were pre-treated with NF-κB inhibitor BAY 11-7085 (2 μM), or JNK inhibitor SP610025 (5 μM), or MEK1/2 inhibitor PD184352 (5 μM), or PI3K inhibitor LY294002 (5 μM) for 2 h prior to SEP treatment. (C) Phagocytosis of pHrodo-E. coli by macrophages were quantified by fluorescence intensity. (D, E) The effects of SEP on protein levels of p-STAT1, p-STAT3 were determined by western blot. The effects of Stattic (5 μM) or Fludarabine (20 μM) on phagocytosis of pHrodo-E. coli were measured by flow cytometry (F), or phagocytosis of live E. coli by gentamicin protection assay (G), or phagocytosis of pHrodo-E. coli by fluorescence intensity (H). All data are represented as mean ± SEM acquired in triplicate determinations. p < 0.05, p < 0.01, ***p < 0.0001.
	FIGURE 4. CD64 is responsible for SEP induced phagocytosis via TLR4/STAT3 signals. (A,B) The effects of SEP on the relative mRNA expression of CD64, CD32 and CD16 were determined by q-PCR. (C,D) The effects of SEP on the protein levels of CD64 and CD16/32 were determined by flow cytometry. (E) RAW264.7 cells were pre-treated with SEP (100 μg/ml) for 24 h, and followed by incubation with 2 μg/ml anti-CD64 or anti-CD16/32 blocking antibodies for 1 h prior to pHrodo-E. coli infection. Then macrophage phagocytosis was quantified by the fluorescence. (F) The effects of blocking CD64 or anti-CD16/32 on phagocytosis of live E. coli by macrophages were measured by gentamicin protection assay. All data are represented as mean ± SEM acquired in triplicate determinations. p < 0.05, p < 0.001,**p < 0.0001. ns, not significant.
	FIGURE 5. SEP promotes filopodia formation via TLR4/STAT3 axis. (A) The effects of SEP on the filopodia formation of macrophages. RAW264.7 cells were administrated with Src family inhibitor AZD0530 (10 μM) or ROCK1 inhibitor Y-27632 (20 μM) for 2 h prior to E. coli infection. The cellular filamentous actin were stained with rhodamine phalloidin and the cellular DNA with DAPI. (B) The effects of SEP on protein levels of p-Src and p-Lyn were determined by western blot. (C) The effects of AZD0530 or Y-27632 on SEP induced phagocytosis of pHrodo-E. coli were measured by fluorescence intensity, (D) or phagocytosis of live E. coli by gentamicin protection assay, or (E) phagocytosis of pHrodo-E. coli by flow cytometry. (F) The effects of TAK-242 or Stattic on SEP induced filopodia formation. (G,H) The effects of TAK-242, or C29, or Stattic, or Fludarabine on SEP induced protein levels of p-Src and p-Lyn were determined by western blot. *p < 0.001, **p < 0.0001.
	FIGURE 6. Inhibition of TLR4 abolishes the protection of SEP against E. coli infection. (A) The experimental design of SEP administration in mice. Mice were treated with SEP (25 mg/kg) or vehicle (saline) by i. v. every 3 days for three times, and sacrificed on the eighth day. The total protein and mRNA were extracted from mice peritoneal macrophages. (B) The protein levels of p-STAT3, p-Src and p-Lyn in the peritoneal macrophages were determined by western blot. (C) The relative mRNA levels of CD64, CD32 and CD16 in the peritoneal macrophages were determined by q-PCR. (D) The experimental design of TAK-242 combined with SEP administration in mice infection model. The TAK-242 group mice were pre-treated with TAK-242 (10 mg/kg, i. p.) 2 h before administration of SEP, once every 3 days for three times. Then mice were further challenged with E. coli (3 × 108 CFU, i. p) on day eight and sacrificed at 18 h post-infection. (n = 8). (E) CFU of E. coli was detected in tissue homogenates of lung, spleen, liver, and peritoneal lavage fluid. (F) MPO value in the lung tissue. (G) The protein levels of CD64 and CD16/32 in the peritoneal macrophages were determined by flow cytometry. (H) The experimental design of TAK-242 combined with SEP administration in mice. The TAK-242 group mice were pre-treated with TAK-242 (10 mg/kg, i. p.) 2 h before administration of SEP, once every 3 days for three times, and sacrificed on the eighth day. (I) The protein levels of p-STAT3, p-Src and p-Lyn in the peritoneal macrophages were determined by western blot. All data are represented as mean ± SEM acquired in triplicate determinations. p < 0.05, p < 0.01, ***p < 0.0001.